Press Resease

Bleeding Disorder Treatment Market by Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others) and by Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic, Fibrin Sealants, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 25-Feb-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-2855 Status : Published

Global bleeding disorder treatment market expected to generate around USD 18.95 billion by 2025, at a CAGR of around 8% between 2019 and 2025. Blood clotting is a mechanism that is activated when an injury results in bleeding inside or outside of the body.

Description

The report covers a forecast and an analysis of the bleeding disorder treatment market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the bleeding disorder treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the bleeding disorder treatment market on a global level.

In order to give the users of this report a comprehensive view of the bleeding disorder treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Bleeding Disorder Treatment Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market.

The study provides a decisive view of the bleeding disorder treatment market by segmenting it on the basis of type, drug class, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further division into major countries including the U.S., the UK, Germany, France, China, Japan, India, Brazil, etc.

Some key players of the global bleeding disorder treatment market are Bayer AG, CSL Behring, Novo Nordisk, Pfizer Inc., Shire PLC, Grifols SA, Octapharma, Amgen Inc., Cangene Corporation, and Alnylam Pharmaceuticals.

This report segments the global bleeding disorder treatment market as follows:

Global Bleeding Disorder Treatment Market: Type Analysis

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Global Bleeding Disorder Treatment Market: Drug Class Analysis

  • Plasma-Derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytic
  • Fibrin Sealants
  • Others

Global Bleeding Disorder Treatment Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global bleeding disorder treatment market, 2016-2025 (USD Billion)
    • 2.2. Global bleeding disorder treatment market: Snapshot
  •  
  • Chapter 3. Bleeding Disorder Treatment Market - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global bleeding disorder treatment market drivers: Impact analysis
      • 3.2.2. The increasing prevalence of bleeding disorders
      • 3.2.3. Government initiatives
      • 3.2.4. Technological advancements
    • 3.3. Market Restraints
      • 3.3.1. Global bleeding disorder treatment market restraints: Impact analysis
      • 3.3.2. Counterfeit treatments
      • 3.3.3. Reimbursement policies
      • 3.3.4. High treatment cost
    • 3.4. Opportunities
      • 3.4.1. R&D activities for the development of recombinant products
    • 3.5. Porter's Five Forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. The threat from new entrants
      • 3.5.4. The threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by type
      • 3.6.2. Market attractiveness analysis, by drug class
      • 3.6.3. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Bleeding Disorder Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global bleeding disorder treatment market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New material launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Bleeding Disorder Treatment Market - Type Analysis
    • 5.1. Global bleeding disorder treatment market: Type overview
      • 5.1.1. Global bleeding disorder treatment market revenue share, by type, 2018 and 2025
    • 5.2. Hemophilia A
      • 5.2.1. Global bleeding disorder treatment market for hemophilia A, 2016-2025 (USD Billion)
    • 5.3. Hemophilia B
      • 5.3.1. Global bleeding disorder treatment market for hemophilia B, 2016-2025 (USD Billion)
    • 5.4. Von Willebrand disease
      • 5.4.1. Global bleeding disorder treatment market for Von Willebrand disease, 2016-2025 (USD Billion)
    • 5.5. Others
      • 5.5.1. Global bleeding disorder treatment market for others, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Bleeding Disorder Treatment Market - Drug Class Analysis
    • 6.1. Global bleeding disorder treatment market: Drug Class overview
      • 6.1.1. Global bleeding disorder treatment market revenue share, by drug class, 2018 and 2025
    • 6.2. Plasma-derived Coagulation Factor Concentrates
      • 6.2.1. Global bleeding disorder treatment market for plasma-derived coagulation factor concentrates pharmacies, 2016-2025 (USD Billion)
    • 6.3. Recombinant Coagulation Factor Concentrates
      • 6.3.1. Global bleeding disorder treatment market for recombinant coagulation factor concentrates, 2016-2025 (USD Billion)
    • 6.4. Desmopressin
      • 6.4.1. Global bleeding disorder treatment market for desmopressin, 2016-2025 (USD Billion)
    • 6.5. Others
      • 6.5.1. Global bleeding disorder treatment market for others, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Bleeding Disorder Treatment Market - Regional Analysis
    • 7.1. Global bleeding disorder treatment market: Regional overview
      • 7.1.1. Global bleeding disorder treatment market revenue share, by region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America bleeding disorder treatment market, 2016-2025 (USD Billion)
      • 7.2.2. North America bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.2.3. North America bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S. bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.2.4.2. The U.S. bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.2.5. Canada
        • 7.2.5.1. Canada bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.2.5.2. Canada bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe bleeding disorder treatment market, 2016-2025 (USD Billion)
      • 7.3.2. Europe bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.3.3. Europe bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.3.4. UK
        • 7.3.4.1. UK bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.3.4.2. UK bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.3.5. Germany
        • 7.3.5.1. Germany bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.3.5.2. Germany bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.3.6. France
        • 7.3.6.1. France bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.3.6.2. France bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of Europe bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.3.7.2. Rest of Europe bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific bleeding disorder treatment market, 2016-2025 (USD Billion)
      • 7.4.2. Asia Pacific bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.4.3. Asia Pacific bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.4.4. China
        • 7.4.4.1. China bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.4.4.2. China bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.4.5. Japan
        • 7.4.5.1. Japan bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.4.5.2. Japan bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.4.6. India
        • 7.4.6.1. India bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.4.6.2. India bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.4.7.2. Rest of Asia Pacific bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America bleeding disorder treatment market, 2016-2025 (USD Billion)
      • 7.5.2. Latin America bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.5.3. Latin America bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.5.4.2. Brazil bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
      • 7.5.5. Rest of Latin America
        • 7.5.5.1. Rest of Latin America bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
        • 7.5.5.2. Rest of Latin America bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa bleeding disorder treatment market, 2016-2025 (USD Billion)
      • 7.6.2. The Middle East and Africa bleeding disorder treatment market revenue, by type, 2016-2025 (USD Billion)
      • 7.6.3. The Middle East and Africa bleeding disorder treatment market revenue, by drug class, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Company Profile
    • 8.1. CSL Behring
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Bayer AG
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Novo Nordisk
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Pfizer Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Shire PLC
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Developments
    • 8.6. Grifols SA
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Developments
    • 8.7. Octapharma
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Developments
    • 8.8. Amgen Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Developments
    • 8.9. Cangene Corporation
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Developments
    • 8.10. Alnylam Pharmaceuticals
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Developments

Methodology

Free Analysis

Blood clotting is a mechanism that is activated when an injury results in bleeding inside or outside of the body. The clotting factors and certain plasma proteins are mainly responsible for the blood clotting mechanism. Blood disorders is a condition that involves malfunctioning of the clotting factors and plasma proteins, where blood clotting mechanism either occurs slowly or doesn’t occur at all.

According to the U.S. Centers for Disease Control and Prevention study, about 1 in 5000 people suffer from hemophilia. According to the WHO (World Health Organization), about 3.2 million of the U.S. population suffers from Von Willebrand disease and more than 14,600 women, men, and children were treated for the same at various hemophilia treatment centers between 2012 and 2016. The increase in the prevalence of bleeding disorders among the population is likely to fuel the growth of the global bleeding disorder treatment market over the estimated timeframe. The growing awareness about the treatment of blood disorders, improvement in the technology for treating these disorders, and growing R&D activities for the development of recombinant factors are other factors projected to drive the global bleeding disorder treatment market in the future. However, the availability of counterfeit treatments and limited reimbursement policies may hinder the bleeding disorder treatment market on a global scale.

Global Bleeding Disorder Treatment Market

The global bleeding disorder treatment market is divided on the basis of type, drug class, and region. By type, the market for bleeding disorder treatment is segmented into hemophilia B, hemophilia A, Von Willebrand disease, and others. The growing prevalence rate of hemophilia A is anticipated to fuel the hemophilia A segment in the global bleeding disorder treatment market. On the basis of drug class, the bleeding disorder treatment market is sectored into plasma-derived coagulation factor concentrates, desmopressin, fibrin sealants, antifibrinolytic, recombinant coagulation factor concentrates, and others. Recombinant coagulation factor concentrates held the maximum share of the blood disorder treatment market globally in 2018. The plasma-derived coagulation factor concentrates segment is expected to show a decline in the growth in the future, due to the risk to acquire blood-related infections.

By region, North America is projected to dominate the global market for blood disorder treatment in the future. This can be attributed to the rising prevalence of hemophilia A, the presence of major players in the region, and increasing population opting for prophylaxis treatment for blood diseases. Asia Pacific is expected to show the highest CAGR in the upcoming years due to the increase in the awareness about blood-related disorders, introduction of government initiatives for the treatment of blood-related disorders, and rapidly developing healthcare infrastructure.

Some key players of the global bleeding disorder treatment market are Bayer AG, CSL Behring, Novo Nordisk, Pfizer Inc., Shire PLC, Grifols SA, Octapharma, Amgen Inc., Cangene Corporation, and Alnylam Pharmaceuticals.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com